← back to search

Yuan Li Shen

United States Food and Drug Administration · US
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, CAR-T cell therapy research, and Lung Cancer Treatments and Mutations.
h-index
35
citations
4,822
works
133
NIH funding
primary concept
Medicine
email

Recent publications

Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective.
2025cited by 11position: contributordoi
Durability of neutralizing antibody and T-cell responses in COVID-19 patients after infection and booster vaccination
Vaccine X 2025cited by 0position: middledoi
Decentralized Clinical Trials in the Era of Real-World Evidence: A Critical Assessment of Recent Experiences.
2025cited by 0position: contributordoi
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.
2024cited by 50position: contributordoi
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.
2024cited by 32position: contributordoi
The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study
ESMO Open 2024cited by 31position: middledoi
Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection
Cell Reports 2024cited by 11position: middledoi
Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations
International Journal of Infectious Diseases 2024cited by 5position: middledoi
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
2023cited by 32position: contributordoi
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.
2023cited by 26position: contributordoi
Distribution characteristics of ABO blood groups in China
Heliyon 2022cited by 18position: middledoi
Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
Statistics in Biopharmaceutical Research 2021cited by 35position: middledoi
Economic evaluation of varicella vaccination strategies in Jiangsu province, China: a decision-tree Markov model
Human Vaccines & Immunotherapeutics 2021cited by 11position: middledoi
MicroRNA‐483 amelioration of experimental pulmonary hypertension
EMBO Molecular Medicine 2020cited by 55position: middledoi
Study on the Influence of Pregnancy-Induced Hypertension on Neonatal Birth Weight
Journal of Investigative Medicine 2018cited by 22position: middledoi
Loss of hypothalamic corticotropin-releasing hormone markedly reduces anxiety behaviors in mice
Molecular Psychiatry 2016cited by 101position: middledoi
Loss of Function of the Melanocortin 2 Receptor Accessory Protein 2 Is Associated with Mammalian Obesity
Science 2013cited by 305position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 5 papers (2023–2025)Richard Pazdur · United States Food and Drug Administration4 papers (2021–2024)Mai‐Juan Ma · Hunan University of Traditional Chinese Medicine3 papers (2024–2025)Xuedong Song · Hebei University of Engineering3 papers (2024–2025)Guojian Yang · Shanghai University3 papers (2024–2025) · 3 papers (2023–2024)Paul G. Kluetz · United States Food and Drug Administration3 papers (2023–2024)Xue-Juan He · Zhengzhou University2 papers (2024–2024)Gang Dong · Shanxi University2 papers (2024–2024) · 2 papers (2013–2016)Herbert Pang · Duke University2 papers (2025–2025)Lianxiang Zhao · Weifang Medical University2 papers (2024–2024)Erhei Dai · Hebei Medical University2 papers (2024–2024)Yu-Wei Zhang · Huzhou Central Hospital2 papers (2024–2025) · 2 papers (2013–2016) · 2 papers (2024–2024)Mingming Wang · Hebei Medical University2 papers (2024–2024)Lola Fashoyin-Aje · Johns Hopkins University2 papers (2023–2024)Steven J. Lemery · Center for Drug Evaluation and Research2 papers (2023–2024)Nadia Daizadeh · Novartis (Switzerland)2 papers (2025–2025)